Marijuana reform opponents have filed briefs previewing the arguments they plan to make in a hearing on the Trump administration’s move to reschedule cannabis that is set to start next week.
Meanwhile, the Drug Enforcement Administration (DEA), which is formally the proponent of the reform to move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III has again made clear it will not be inviting supporters of rescheduling to participate.
A brief from the states of Idaho, Indiana and Nebraska says that each of them “prohibits or severely restricts the availability of marijuana within its borders, as marijuana causes our citizens psychiatric harm and is linked to increases in homelessness, traffic accidents, illegal drug trafficking, and other crime.”
The states said they intend to call Deepak Cyril D’Souz, the inaugural director of the Yale Center for the Science of Cannabis and
Cannabinoids, as a witness in the hearing.
“He is expected to testify regarding the abuse liability of cannabis, drawing upon evidence from controlled human laboratory studies, brain imaging, and epidemiologic research,” the statement says. “The available scientific evidence demonstrates that regular cannabis use can lead to cannabis use disorder in a substantial proportion of users.”
It
Read full article on Marijuana Moment
